Fudan University Cancer Center
Shanghai, Shanghai Municipality, 200032, China
NCT Number: NCT05252676
This study is one of the Eastern Cooperative Thoracic Oncology Projects (ECTOP-1011). It aims to evaluate the correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma via whole-mount section.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Shanghai, Shanghai Municipality, 200032, China
The pathological lepidic growth pattern was believed to relate to the ground-glass component, whereas invasive adenocarcinoma patterns relate to the solid component. However, the solid components might be fibrosis rather tumor; and previous studies demonstrated the ground-glass components might be invasive lesions. Therefore, it is of considerable significance to establish the correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: about 14 days
Evaluation of correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma
Time frame: about 14 days
The specificity, sensitivity, and repeatability of invasiveness diagnosis based on the Whole-Mount Section
Fudan University
Other
Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of Ground Glass Opacity Featured Lung Adenocarcinoma Via Whole-Mount Section
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04566432
Adenocarcinoma, Adenocarcinoma of Lung
Shanghai, China
View Trial DetailsNCT03184571
Adenocarcinoma, Adenocarcinoma of Lung
Lebanon, New Hampshire, United States
View Trial DetailsNCT05292859
Adenocarcinoma, Adenocarcinoma of Lung
Houston, Texas, United States
View Trial DetailsNCT03676192
Adenocarcinoma, Adenocarcinoma of Lung
Seoul, South Korea
View Trial Details